Bliss GVS Pharma Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Bliss GVS Pharma.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Investors Don't See Light At End Of Bliss GVS Pharma Limited's (NSE:BLISSGVS) Tunnel

Nov 23

Here's Why Bliss GVS Pharma (NSE:BLISSGVS) Has Caught The Eye Of Investors

Oct 26

These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Safely

Aug 25

Bliss GVS Pharma Limited's (NSE:BLISSGVS) Prospects Need A Boost To Lift Shares

Aug 07

Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now

Jul 19

There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding

Jan 26

Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?

Jul 14

Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50

Sep 11

Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50

Aug 28

These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well

May 21

Estimating The Intrinsic Value Of Bliss GVS Pharma Limited (NSE:BLISSGVS)

Apr 08

A Look At Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Returns

Mar 18

Here's How We Evaluate Bliss GVS Pharma Limited's (NSE:BLISSGVS) Dividend

Feb 25

Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet

Feb 08

What Type Of Shareholders Make Up Bliss GVS Pharma Limited's (NSE:BLISSGVS) Share Registry?

Jan 21

Do Its Financials Have Any Role To Play In Driving Bliss GVS Pharma Limited's (NSE:BLISSGVS) Stock Up Recently?

Jan 08

How Is Bliss GVS Pharma's (NSE:BLISSGVS) CEO Paid Relative To Peers?

Dec 26

Did Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Deserve to Gain 14%?

Dec 13

Should You Use Bliss GVS Pharma's (NSE:BLISSGVS) Statutory Earnings To Analyse It?

Nov 30

Bliss GVS Pharma Limited (NSE:BLISSGVS) Insiders Increased Their Holdings

Nov 18

Does Bliss GVS Pharma Limited (NSE:BLISSGVS) Have A Place In Your Dividend Portfolio?

Nov 06

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Bliss GVS Pharma no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:BLISSGVS - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	8,002	634	601	1,051	N/A
6/30/2024	7,944	815	N/A	N/A	N/A
3/31/2024	7,702	755	1,241	1,524	N/A
12/31/2023	7,569	879	N/A	N/A	N/A
9/30/2023	7,619	883	505	1,026	N/A
6/30/2023	7,224	598	N/A	N/A	N/A
3/31/2023	7,516	709	-595	343	N/A
12/31/2022	7,339	871	N/A	N/A	N/A
9/30/2022	7,444	91	N/A	N/A	N/A
6/30/2022	7,680	165	N/A	N/A	N/A
3/31/2022	7,475	150	615	1,355	N/A
12/31/2021	7,124	17	N/A	N/A	N/A
9/30/2021	6,602	773	-86	434	N/A
6/30/2021	6,158	766	N/A	N/A	N/A
3/31/2021	5,772	685	548	640	N/A
12/31/2020	5,650	710	N/A	N/A	N/A
9/30/2020	5,487	692	873	943	N/A
6/30/2020	6,073	797	N/A	N/A	N/A
3/31/2020	6,893	973	-126	467	N/A
12/31/2019	8,136	1,066	N/A	N/A	N/A
9/30/2019	8,861	1,087	-674	267	N/A
6/30/2019	9,044	1,192	N/A	N/A	N/A
3/31/2019	8,986	1,237	-38	400	N/A
12/31/2018	3,788	623	N/A	N/A	N/A
9/30/2018	3,543	543	N/A	N/A	N/A
6/30/2018	3,521	469	N/A	N/A	N/A
3/31/2018	3,720	297	N/A	176	N/A
12/31/2017	9,063	1,098	N/A	N/A	N/A
9/30/2017	9,423	1,053	N/A	N/A	N/A
6/30/2017	8,843	860	N/A	N/A	N/A
3/31/2017	4,033	509	N/A	2,895	N/A
12/31/2016	6,711	664	N/A	N/A	N/A
9/30/2016	5,755	742	N/A	N/A	N/A
6/30/2016	5,911	836	N/A	N/A	N/A
3/31/2016	5,469	825	N/A	1,129	N/A
3/31/2015	4,071	599	N/A	376	N/A
3/31/2014	3,446	410	N/A	412	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de BLISSGVS es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de BLISSGVS crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de BLISSGVS crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de BLISSGVS crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de BLISSGVS crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BLISSGVS se prevé que sea elevada dentro de 3 años.

Bliss GVS Pharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investors Don't See Light At End Of Bliss GVS Pharma Limited's (NSE:BLISSGVS) Tunnel

Second quarter 2025 earnings released: EPS: ₹2.31 (vs ₹4.06 in 2Q 2024)

Here's Why Bliss GVS Pharma (NSE:BLISSGVS) Has Caught The Eye Of Investors

Investor sentiment deteriorates as stock falls 22%

Bliss GVS Pharma Limited Appoints Nandkumar Kashinath Chodankar as Chairman of the Board

Now 24% undervalued

Bliss GVS Pharma Limited to Report Q2, 2025 Results on Oct 24, 2024

Bliss GVS Pharma Limited to Report Q2, 2025 Results on Oct 24, 2024

Bliss GVS Pharma Limited Announces Cessation of Subramanian Ramaswamy Vaidya as an Independent Director

These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Safely

Investor sentiment improves as stock rises 18%

Bliss GVS Pharma Limited's (NSE:BLISSGVS) Prospects Need A Boost To Lift Shares

Bliss GVS Pharma Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Now 20% undervalued after recent price drop

Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now

Bliss GVS Pharma's (NSE:BLISSGVS) Dividend Will Be ₹0.50

Bliss GVS Pharma Limited to Report Q1, 2025 Results on Jul 24, 2024

Upcoming dividend of ₹0.50 per share

Full year 2024 earnings released: EPS: ₹7.23 (vs ₹6.83 in FY 2023)

Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50

We Think Bliss GVS Pharma's (NSE:BLISSGVS) Solid Earnings Are Understated

Dividend of ₹0.50 announced

Now 23% undervalued after recent price drop

Full year 2024 earnings released: EPS: ₹7.23 (vs ₹6.83 in FY 2023)

Bliss GVS Pharma Limited, Annual General Meeting, Jul 25, 2024

Bliss GVS Pharma Limited to Report Q4, 2024 Results on May 02, 2024

Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Right But Growth Is Lacking

Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 16%

Insufficient new directors

There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding

Third quarter 2024 earnings released: EPS: ₹2.64 (vs ₹2.68 in 3Q 2023)

New major risk - Share price stability

Bliss GVS Pharma Limited to Report Q3, 2024 Results on Jan 23, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹4.06 (vs ₹1.33 in 2Q 2023)

Investor sentiment improves as stock rises 20%

Bliss GVS Pharma Limited to Report First Half, 2024 Results on Nov 01, 2023

Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao

First quarter 2024 earnings released: EPS: ₹1.41 (vs ₹2.48 in 1Q 2023)

Bliss GVS Pharma Limited to Report Q1, 2024 Results on Aug 01, 2023

Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Investor sentiment improves as stock rises 17%

Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?

Upcoming dividend of ₹0.50 per share at 0.7% yield

Full year 2023 earnings released: EPS: ₹6.83 (vs ₹1.46 in FY 2022)

Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

Bliss GVS Pharma Limited, Annual General Meeting, Jun 19, 2023

Bliss GVS Pharma Limited to Report Q4, 2023 Results on May 11, 2023

Insider recently bought ₹23m worth of stock

Third quarter 2023 earnings released: EPS: ₹2.68 (vs ₹4.83 loss in 3Q 2022)

Bliss GVS Pharma Limited to Report Q3, 2023 Results on Jan 24, 2023

Bliss GVS Pharma Limited Appoints Mr. Deepak Sawant as Chief Financial Officer

Second quarter 2023 earnings released: EPS: ₹1.33 (vs ₹2.05 in 2Q 2022)

Bliss GVS Pharma Limited to Report Q2, 2023 Results on Nov 07, 2022

First quarter 2023 earnings released: EPS: ₹2.48 (vs ₹2.35 in 1Q 2022)

Bliss GVS Pharma Limited to Report Q1, 2023 Results on Aug 03, 2022

Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹0.50 per share

Executive & Whole Time Director recently bought ₹21m worth of stock

Full year 2022 earnings released

Bliss GVS Pharma Limited Announces Resignation of Mr. Vipul B. Thakkar as Chief Financial Officer

Executive & Whole Time Director recently bought ₹9.5m worth of stock

Investor sentiment improved over the past week

Bliss GVS Pharma Limited, Annual General Meeting, Jun 28, 2022

Bliss GVS Pharma Limited to Report Q4, 2022 Results on Apr 30, 2022

Executive & Whole Time Director recently bought ₹26m worth of stock

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹2.05 (vs ₹1.99 in 2Q 2021)

Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50

Upcoming dividend of ₹0.50 per share

Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50

First quarter 2022 earnings released: EPS ₹2.35 (vs ₹1.57 in 1Q 2021)

These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well